Are there variations in adherence to colorectal cancer clinical guidelines depending on treatment place and recommendation novelty? The French EvaCCoR observational study.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
06 2019
Historique:
received: 26 03 2018
revised: 29 08 2018
accepted: 15 10 2018
pubmed: 19 11 2018
medline: 21 4 2020
entrez: 19 11 2018
Statut: ppublish

Résumé

Studies have shown clinical practices variation between centers in colorectal cancer (CRC) management. After the implementation of national cancer plans, we tested for differences in center and patients' socioeconomic position (SEP)-related variation in CRC guidelines. All patients aged 18 years and over, cared for a first CRC in 2010 in Southwest of France. We used mixed effect model to test for center-related heterogeneity (CRH) in recommendation, from the oldest to the more recent: (1) at least 12 lymph nodes analysed for stage II, (2) the prescription of adjuvant chemotherapy stage III and (3) the assessment of CRC molecular phenotype regarding KRAS status for stage IV. Patients' SEP was approached by an ecological social deprivation index. We found: higher adherence for the oldest than for the most recent recommendations; no CRH in recommendation No. 2 but lower adherence in academic centers; a CRH for recommendations No. 1 and 3; no SEP-related differences in clinical practices. Results showed that older recommendations have higher adherence but did not support increasing influence of centers characteristics and CRH as recommendations are more recent.

Sections du résumé

BACKGROUND
Studies have shown clinical practices variation between centers in colorectal cancer (CRC) management. After the implementation of national cancer plans, we tested for differences in center and patients' socioeconomic position (SEP)-related variation in CRC guidelines.
METHODS
All patients aged 18 years and over, cared for a first CRC in 2010 in Southwest of France. We used mixed effect model to test for center-related heterogeneity (CRH) in recommendation, from the oldest to the more recent: (1) at least 12 lymph nodes analysed for stage II, (2) the prescription of adjuvant chemotherapy stage III and (3) the assessment of CRC molecular phenotype regarding KRAS status for stage IV. Patients' SEP was approached by an ecological social deprivation index.
RESULTS
We found: higher adherence for the oldest than for the most recent recommendations; no CRH in recommendation No. 2 but lower adherence in academic centers; a CRH for recommendations No. 1 and 3; no SEP-related differences in clinical practices.
CONCLUSION
Results showed that older recommendations have higher adherence but did not support increasing influence of centers characteristics and CRH as recommendations are more recent.

Identifiants

pubmed: 30447905
pii: S2210-7401(18)30224-9
doi: 10.1016/j.clinre.2018.10.008
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

346-356

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

S Lamy (S)

University of Toulouse III Paul-Sabatier, 31000 Toulouse, France; Department of clinical pharmacology, Toulouse university hospital, 31000 Toulouse, France; Inserm UMR1027 (The French national institute of health and medical research), 31000 Toulouse, France. Electronic address: sebastien.lamy@univ-tlse3.fr.

R Guimbaud (R)

Digestive medical oncology unit, Toulouse university hospital, Toulouse university cancer institute (IUCT-O), 31100 Toulouse, France; Occitanie regional cancer network (Onco-Occitanie), 31100 Toulouse, France.

L Digue (L)

Aquitaine regional cancer network, 33076 Bordeaux, France; Department of clinical oncology, Bordeaux university hospital, 33000 Bordeaux, France.

I Cirilo-Cassaigne (I)

Aquitaine regional cancer network, 33076 Bordeaux, France.

V Bousser (V)

Aquitaine regional cancer network, 33076 Bordeaux, France.

E Oum-Sack (E)

Occitanie regional cancer network (Onco-Occitanie), 31100 Toulouse, France.

J Goddard (J)

Occitanie regional cancer network (Onco-Occitanie), 31100 Toulouse, France.

E Bauvin (E)

Occitanie regional cancer network (Onco-Occitanie), 31100 Toulouse, France.

C Delpierre (C)

Inserm UMR1027 (The French national institute of health and medical research), 31000 Toulouse, France.

P Grosclaude (P)

Inserm UMR1027 (The French national institute of health and medical research), 31000 Toulouse, France; Tarn cancers registry, 81000 Albi, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH